The Joplin Globe

Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

This patent covers our drug-device combination through March 2043,” said Matt Pauls, J.D., M.B.A, Chair and Chief Executive Officer, Savara. “With 10 years of Orphan Drug regulatory exclusivity upon ...
TipRanks on MSN

Savara issues patent for Molbreevi from European Patent Office

Savara (SVRA) announced the European Patent Office has issued patent No. 4 496 611 titled, “Drug-Device Combination Comprising a Liquid Solution ...
Business Insider

LAMIRA®, an eFlow® Technology nebulizer, expected to launch in Japan as a medical device for exclusive administration of ARIKAYCE® (amikacin liposome inhalation suspension)

STARNBERG, Germany, March 24, 2021 /PRNewswire/ -- PARI Pharma GmbH, a company focused on advanced aerosol delivery systems based on eFlow Technology, announces the authorization of the LAMIRA ...
Business Wire

Kamada Granted Key New Patent for Inhaled AAT and eFlow® Nebulizer System in Israel

NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, reports that the Israeli Patent Office (ILPO) ...